Primary and secondary stroke prevention

Current Opinion in Neurology

Volumn 9, Issue 1, 1996, Pages 46-52

  Feinberg, William M ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DIPYRIDAMOLE; ESTROGEN; LIPID; TICLOPIDINE; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; BONE MARROW SUPPRESSION; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CIGARETTE SMOKING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTROGEN THERAPY; FEMALE; HUMAN; HYPERTENSION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SECONDARY PREVENTION; SHORT SURVEY; STROKE;

EID: 0029881056     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199602000-00010     Document Type: Short Survey

References (63)

1. Raps EC, Galetta SL: Stroke prevention therapies and management of patient subgroups. Neurology 1995, 45(Suppl 1):S19-S24.
2. Albers GW: Antithrombotic agents in cerebral ischemia. Am J Cardiol 1995, 75:34B-38B.
3. Barnett HJ, Eliasziw M, Meldrum HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med 1995, 332:238-248. An excellent up-to-date review of medications and surgery for stroke prevention. Includes some new meta-analysis of antiplatelet therapy trials. This review concentrates on data from randomized clinical trials.
4. Gorelick PB: Stroke prevention. Arch Neurol 1995. 52:347-355. A current review of both primary and secondary stroke prevention strategies. It also reviews stroke prevention as a public health issue.
5. Sacco RL: Risk factors and outcomes for ischemic stroke. Neurology 1995, 45(Suppl 1):S10-S14.
6. Sherman DG, Dyken Jr ML, Gent M, Harrison MJG, Hart RG, Mohr JP: Antithrombotic therapy for cerebrovascular disorders. Fourth Accl Consensus Conference Antithrombotic Therapy. Chest 1995, 108(Suppl):444S-456S. This conference has become an influential source for therapy recommendations. The latest update provides a review of the stroke syndrome and recent trials and provides consensus therapy recommendations. Several new figures and tables are helpful.
7. Feinberg WM, Albers GW, Barnett HJM, Miller J, Caplan LR, Carter LP, Hart RG, Hobson II RW, Kronmal RA, Moore WS, et al.: American Heart Association Medical/Scientific Statement: guidelines for management of transient ischemic attacks. Stroke 1994, 25:1320-1335. This consensus panel included neurologists, vascular surgeons, and neurosurgeons. The report includes a review of the TIA syndrome as well as recommendations for diagnostic workup and therapy.
8. Adams HP, Brott TG, Crowell RM, Furlan AJ, Gomez CR, Grotta J, Helgason CM, Marler JR, Woolson RF, Zivin JZ et al.: American Heart Association Medical/Scientific Statement: guidelines for the management of patients with acute ischemic stroke. Stroke 1994, 25:1901-1914. A comprehensive review of stroke and stroke therapy, with recommendations for diagnostic workup and treatment. This consensus panel included neurologists, vascular surgeons, and neurosurgeons.
9. Moore WS, Barnett HJ, Beebe HG, Bernstein EF, Brener BJ, Frott T, Caplan LR, Day A, Goldstone J, Hobson RW Jr et al.: Guidelines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee, American Heart Association. Stroke 1995, 26:188-201. Indications for carotid endarterectomy were graded as 'proven', 'acceptable but not proven', 'uncertain', or 'proven inappropriate'. This multidisciplinary consensus conference reviewed and graded 96 possible indications. The paper also includes a review of the natural history of carotid disease and clinical trials.
10. Gorelick PB: Stroke prevention. An opportunity for efficient utilization of health care resources during the coming decade. Stroke 1994, 25:220-224.
11. Wolf P, Cobb J, D'Agostino R: Chapter 1, Epidemiology of stroke. In Stroke - pathophysiology, diagnosis, and management. Edited by Barnett HJM, Mohr JP, Stein BM, Yatsu FM. New York: Churchill Livingstone; 1992:3-27.
12. Welin L, Svardsudd K, Wilhelmsen L, Larsson B, Tibblin G: Analysis of risk factors for stroke in a cohort of men born in 1913. N Engl J Med 1987, 317:521-526.
13. Collins R, Peto R, MacMahon S, Hebert P, Fiebach NH, Eberlein KA, Godwin J, Qizilbash N, Taylor JO, Hennekens CH: Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990, 335:827-838.
14. SHEP Cooperative Research Group: Prevention of stroke by anti-hypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1991, 265:3255-3264
15. Sutton-Tyrrell K, Alcorn HG, Herzog H, Kelsey SF, Kuller LH: Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995, 26:1319-1324.
16. Colditz G, Bonita R, Stampfer M, Willett W, Rosner B, Speizer F, Hennekens C: Cigarette smoking and risk of stroke in middle-aged women. N Engl J Med 1988, 318:937-941.
17. Wolf P, D'Agostino R, Kannel W, Bonita R, Belanger A: Cigarette smoking as a risk factor for stroke. JAMA 1988, 259:1025-1029.
18. Wannamethee SG, Shaper AG, Whincup PH, Walker M: Smoking cessation and the risk of stroke in middle-aged men. JAMA 1995, 274:155-160.
19. Atkins D, Psaty BM, Koepsell TD, Longstreth WT Jr, Larson EB: Cholesterol reduction and the risk of stroke in men. A meta-analysis of randomized, controlled trials. Ann Int Med 1993, 119:136-145.
20. The Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383-1389. This randomised clinical trial showed a 30% reduction in stroke in the treated group. This was the first trial to suggest that cholesterol lowering may have a role in stroke prevention.
21. Furberg CD, Adams HP Jr, Applegate WB, Byington RP, Espeland MA, Hartwell T, Hunningbake DB, Lefkowitz DS, Probstfield J, Riley WA: Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic carotid artery progression study (ACAPs) research group. Circulation 1994, 90:1679-1687.
22. Crouse JR, Byington RP, Bond MG, Espeland MG, Craven TE, Sprinkle JW, McGovern ME, Furberg GD: Pravastatin, lipids, and atherosclerosis in the carotid arteries (PLAC-II). Am J Cardiol 1995, 75:455-459.
23. Stampfer M, Colditz G, Willett W, Manson J, Rosner B, Speizer F, Hennekens C: Postmenopausal estrogen therapy and cardiovascular disease. N Engl J Med 1991, 325:756-762.
24. Finucane FF, Madans JH, Bush TL, Wolf PH, Kleinman JC: Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med 1993, 153:73-79.
25. Davidson NE: Hormone-replacement therapy - breast versus heart versus bone [Editorial]. N Engl J Med 1995, 332:1638-1639
26. Major ongoing stroke trials. Stroke 1995, 26:1140-1144.
27. Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308: 81-106.
28. Steering Committee of the Physicians' Health Study Research Group: Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135.
29. Dyken ML, Barnett HJM, Easton JD, Fields WS, Fuster V, Hachinski V, Norris JW, Sherman DG: Low-dose aspirin and stroke: 'it ain't necessarily so.' Stroke 1992, 23:1395-1399.
30. van Gijn J, Warlow CP, Norrving B: Low-dose aspirin and stroke [Letter]. Stroke 1993, 24:476.
31. UK-TIA Study Group: United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
32. Bornstein NM, Karepov VG, Aronovich BD. Failure of aspirin treatment after stroke. Stroke 1994, 25:275-277.
33. Helgason CM, Bolin KM, Hoff JA, Winkler SR, Mangat A, Tortorice KL, Brace LD: Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994, 24:2331-2336.
34. Ackerman RH, Newman KL: Incomplete antiplatelet effect in patients on aspirin compounds [Abstract]. Ann Neurol 1990, 28:224.
35. Gent M, Blakely JA, Easton JD, Ellis DJ, Hachinski VC, Harbison JW, Panak E, Roberts RS, Sicurella J, Turpie AG: The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1988, ii: 1211-1220
36. Hass WK, Easton JD, Adams HP Jr, Pryse-Phillips W, Molony BA, Anderson S, Kamm B, for the Ticlopidine-Aspirin Stroke Study Group: A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989, 321:501-507.
37. Shear NH, Appel C: Prevention of ischemic stroke [Letter]. N Engl J Med 1995, 333:460. The authors described six cases of fatal bone marrow suppression associated with ticlopidine. This contradicts the statement in most recent reviews that the neutropenia associated with ticlopidine is always reversible.
38. Oster G, Huse DM, Lacey MJ, Epstein AM: Cost effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994, 25:1149-1156.
39. van Gijn J, Algra A: Ticlopidine, trials, and torture [Editorial]. Stroke 1994, 25:1097-1098.
40. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG: Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med 1995, 155:469-473. Half of the people with atrial fibrillation in the USA are over the age of 75 years, and over half are women. This epidemiologic review has implications for generalizing the results from the atrial fibrillation clinical trials.
41. Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions. Arch Intern Med 1994, 154:1443-1448. This clear and concise review summarizes the recent atrial fibrillation trials and new epidemiologic data. It does an excellent job in putting the data in content. The review provides recommendations for current management, and indicates where areas of uncertainty remain.
42. Laupacis A, Albers GW, Dalen JE, Dunn M, Feinberg WM, Jacobson A: Antithrombotic therapy for atrial fibrillation. Fourth ACCP Consensus Conference on Antithrombotic Therapy. Chest 1995, 108(Suppl):352S-359S. This consensus conference has become an influential standard. This review summarizes the clinical trials and provides recommendations regarding anti-thrombotic therapy in these patients.
43. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994, 154: 1449-1457. The authors of five recent atrial fibrillation primary prevention trials pooled their data to produce a larger database. This analysis provides the best information on risk factors for stroke in atrial fibrillation. It also provides more powerful data on the effect of warfarin and aspirin.
44. Petersen P, Boysen G, Gotfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications of chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989, 1:175-179.
45. The Stroke Prevention in Atrial Fibrillation Investigators: The Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991, 84: 527-539.
46. Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994, 343:687-691.
47. Hart RH, Halperin JL: Atrial fibrillation and stroke: revisiting the dilemmas. Stroke 1994, 25:1337-1341.
48. European Atrial Fibrillation Study Group: Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993, 342:1255-1262.
49. Sansoy V, Abbott RD, Jayaweera AR, Kaul S: Low yield of transthoracic echocardiography for cardiac source of embolism. Circulation 1995, 75:166-169. Retrospective review of 1010 consecutive transthoracic echocardiograms ordered to rule out cardiac source of emoblism found a highly probable cardiac source in less than 3%. This was no different from the prevalence in 325 echocardiograms ordered for other reasons during the same period.
50. Comess KA, DeRook FA, Beach KW, Lytle NJ, Golby AJ, Albers GW: Transesophageal echocardiography in patients with cerebral ischemia: prevalence of findings and recurrent stroke risk. JACC 1994, 23: 1598-1603. Transesophageal echocardiography identified a potential cardiac source in 45% of 145 consecutive stroke and TIA patients. In prospective follow-up those with abnormal findings had a higher rate of recurrent events.
51. Cabanes L, Mas JL, Cohen A, Amarenco P, Cabanes PA, Oubary P, Chedru F, Guerin F, Bousser MG, de Recondo J: Atrial septal aneurysm and patent foramen ovale as risk factors for cryptogenic stroke in patients less than 55 years of age: a study using transesophageal echocardiogiaphy. Stroke 1993, 24:1865-1873.
52. Leung DY, Black IW, Cranney GB, Hopkins AP, Walsh WF: Prognostic implications of left atrial spontaneous echo contrast in nonvalvular atrial fibrillation. JACC 1994, 24:755-762.
53. Stoddard MF, Dawkins PR, Prince CR, Ammash NM: Left atrial appendage thrombus is not uncommon in patients with acute atrial fibrillation and a recent embolic event: a transesophageal echocardiographic study. JACC 1995, 25:452-459.
54. Amarenco P, Cohen A, Tzourio C, Bertrand B, Hommel M, Besson G, Chauvel C, Touboul PJ, Bousser MG: Atherosclerotic disease of the aortic arch and the risk of ischemic stroke. N Engl J Med 1994, 331:1474-1479. This case-control study suggests that atheromotous disease of the aortic arch may be an important and underrecognized source of stroke. The clinical implications of these findings need to be examined in a prospective trial.
55. Wilterdink JL, Easton JD: Vascular event rates in patients with atherosclerotic cerebrovascular disease. Arch Neurol 1992, 49:857-863.
56. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study: Endarterectomy for asymptomatic carotid artery stenosis. JAMA 1995, 273:1421-1428. This long-awaited study found a 55% reduction in stroke risk with carotid endarterectomy compared with medical therapy alone in asymptomatic carotid stenosis. The absolute risk reduction was small, about 1% per year. The benefit was much less in women, primarily because of a higher surgical complication rate.
57. Mayberg M: Endarterectomy for asymptomatic carotid artery stenosis. Resolving the controversy. JAMA 1995, 273:1459-1461.
58. North American Symptomatic Carotid Endarterectomy Trial Collaborators: Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 1991, 325:445-453.
59. European Carotid Surgery Trialists' Collaborative Group: MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or mild (0-29%) carotid stenosis. Lancet 1991, 337:1235-1243.
60. Mayberg MR, Wilson SE, Yatsu F, Weiss DG, Messina L, Hershey LA, Colling C, Eskridge J, Deykin D, Winn HR, for the Veterans Affairs Cooperative Studies Program 309 Trialist Group: Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. JAMA 1991, 266:3289-3294.
61. Eliasziw M, Smith RF, Singh N, Holdsworth DW, Fox AJ, Barnett HJM, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group: Further comments on the measurement of carotid stenosis from angiograms. Stroke 1994, 25:2445-2449.
62. Rothwell PM, Gibson RJ, Slattery J, Sellar RJ, Warlow CP for the European Carotid Surgery Trialists' Collaborative Group: Equivalence of measurements of carotid stenosis - a comparison of three methods on 1001 angiograms. Stroke 1994, 25:2435-2439.
63. Beebe HG, Clagett GP, DeWeese JA, Moore WS, Robertson JT, Sandok B, Wolf PA: Assessing risk associated with carotid endarterectomy. A statement for health professionals by an Ad Hoc Committee on Carotid Surgery Standards of the Stroke Council, American Heart Association. Stroke 1989, 20:314-315.